Opening the door to biosimilar competition starts with breaking down the patent barrier, says Christine Simmon, JD.
With multiple issues preventing biosimilar-induced price reduction, Christine Simmon, JD, is working to remove legal hurdles and foster patent transparency for biosimilar manufacturers.
Simmon is senior vice president of policy and strategic alliances for the trade association Association for Accessible Medicines (AAM). She is also executive director of the Biosimilars Council a division of the AAM, which represents many large drug manufacturers.
Many of the 17 biosimilars currently marketed in the United States have had to face ruthless legal disputes with reference product manufacturers that fought to keep biosimilar competitors off the market for as long as possible. The first FDA-approved biosimilar—Sandoz’s filgrastim biosimilar, Zarxio—entered the market 6 months after receiving regulatory approval but for others the journey to market may take years. Two etanercept biosimilars have FDA approvals but may not reach market until 2029.
The Patent Battle
In an interview with Managed Healthcare Executive®, Simmon said one of her main fights is to see reforms on what patents can cover. “It’s very common for a brand-name biologic manufacturer to obtain as many patents as possible,” she said. Patents may cover a variety of aspects beyond the biologic drug itself including specific language on product labels.
Those patents enable originator manufacturers to block biosimilar manufacturers with lengthy and expensive court battles or settlements that include biosimilar manufacturers agreeing to delay the launch or regulatory filing for its biosimilar, she said.
In the case of AbbVie and adalimumab (Humira), a reference product, patent protections have delayed market entry until 2023 for 6 FDA-approved biosimilar competitors. AbbVie has 136 patents for Humira, a portfolio of legal protection that is typically referred to as a patent “thicket.”
The Dispute Legal Process
Simmon noted that she would like to preserve the opportunity for pharmaceutical companies to enter into patent settlement agreements as a way to quickly resolve legal disputes. She also wants more patent disputes to enter the inter partes review process before the Patent and Trademark Board within the US Patent and Trademark Office, a quicker way for manufacturers to challenge drug patents.
Increase Patent Transparency
Additionally, Simmon wants to help the FDA to find a better way for biosimilar manufacturers to know which patents they may be challenged on, without the need to hire costly law firms.
She noted that currently, there is no easy way for interested parties to know which patents exist for certain products.
In a previous interview with The Center for Biosimilars®, Simmon said a great solution for this would be for the FDA to list patents in the Purple Book, which is an online directory for biologic products. The Biologic Patent Transparency Act that was initiated by Senator Susan Collins, R-Maine, is designed to require greater disclosure of patents and is a key piece of legislation that Simmon in conjunction with the AAM is working to get passed.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.